Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Gilberto de Castro Jr
Gilberto de Castro Jr received his MD degree from the University of Sao Paulo Medical School, Brazil in 1995, and completed his training in Internal Medicine and Clinical Oncology in 2000 at Hospital das Clínicas, University of Sao Paulo Medical School, where he also received his PhD degree in 2009. He is an ex fellow of the Medical Oncology Clinic at the Institut Jules Bordet, Brussels, Belgium. His current position is Chief at the Unit of Head and Neck and Thoracic Tumors of the Clinical Oncology Service of the Instituto do Cancer do Estado de Sao Paulo, Brazil - the largest cancer center in the South America. Dr Castro has more than 50 publications in peer-reviewed journals and his areas of interest are the medical management of head and neck cancer and thoracic malignancies, focusing on the development of molecular targeted therapies, predictive factors of response to chemotherapy, treatment-related toxicity and quality of life studies.
Arif Hussain, MD is Professor of Medicine with Tenure in the Department of Medicine, School of Medicine, at the University of Maryland in Baltimore, USA, where he is also Professor of Biochemistry in the Department of Biological Chemistry and Professor of Pathology in the Department of Pathology. He also serves as Co-Leader of the Hormone Responsive Cancers Program in the Greenebaum Cancer Center, University of Maryland. Dr Hussain's clinical interest is in genitourinary cancers, and he serves as Principal Investigator on several clinical trials that focus on therapies for high risk, recurrent and metastatic prostate cancer, as well as renal cell cancer. In addition, he has a research laboratory focusing on drug resistance, intracellular calcium pumps, and pre-clinical models of prostate cancer.